In exchange, Pfizer has agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In addition, Melior has agreed to utilize its in-vivo theraTRACE indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer.
Andrew Reaume, president and CEO of Melior, said: “This is the second collaboration initiated with Pfizer in the last 18 months and we look forward to this expansion to our productive R&D relationship.”